Nasal spray weight loss drug enters human testing
NCT ID NCT07465965
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new nasal spray form of semaglutide (a weight-loss drug) in 60 overweight or obese adults. The main goal is to check safety and how the body processes the drug, not to prove weight loss yet. Participants receive a single dose and are monitored closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Frontage Clinical Services, Inc.
RECRUITINGSecaucus, New Jersey, 07094, United States
Contact Phone: •••-•••-••••